BioPharm Insight’s diverse team consistently provides an exceptional product and level of analysis to a readership comprising: top-tier investment banks, hedge funds and corporate subscribers in the healthcare sector. BioPharm Insight is a part of GlobalData, plc.
What you will do
Investigate potential market-moving situations in the biopharmaceutical space
Interview and build a comprehensive source book of key opinion leaders, physicians and industry experts
Write in-depth analysis pieces and break news with a target of 3-4 stories a week
Travel across the US or Europe (depending on location) to cover academic and industry conferences
Attend regular source meetings and events to build solid rapport with industry experts
What you will bring to the table
Scientific and/or journalism background as well as a demonstrable understanding of the pharmaceutical industry and R&D landscape
Experience covering oncology, cardiovascular diseases, metabolic diseases, rheumatic diseases, eye diseases or bone diseases
Previous experience on a daily or weekly healthcare-related publication
Excellent communication, networking, writing and interviewing skills
Ability to work in an interactive, time-sensitive and deadline-driven environment (often accommodating different global time zones)
Adaptable to working independently as well as with a team-oriented reporting approach.
To apply, please email US Editor – Surani Fernando – sfernando@biopharminsight.com
CNBC senior vice president Dan Colarusso sent out the following on Monday: Before this year comes to…
Business Insider editor in chief Jamie Heller sent out the following on Monday: I'm excited to share…
Former CoinDesk editorial staffer Michael McSweeney writes about the recent happenings at the cryptocurrency news site, where…
Manas Pratap Singh, finance editor for LinkedIn News Europe, has left for a new opportunity…
Washington Post executive editor Matt Murray sent out the following on Friday: Dear All, Over the last…
The Financial Times has hired Barbara Moens to cover competition and tech in Brussels. She will start…